Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being

Figures & data

Table 1 Demographics

Characteristic	Patients (N=487)
Age, mean (SD)	38.2 (11.75)
Sex, n (%)
Female	164 (33.7)
Male	323 (66.3)
Race, n (%)
African	30 (6.2)
Caucasian	327 (67.1)
East Asian	22 (4.5)
Hispanic	92 (18.9)
Native American	1 (0.2)
West Asian (Indian subcontinent)	15 (3.1)

Notes: N, number of patients; n, number of affected patients.

Figure 1 Patient responses on the PSMQ-Mod: before and after implementation of the 3-hour observation period.

Note: n, number of patients.
Abbreviations: LAI, long-acting injection; PSMQ-Mod, Patient Satisfaction with Medication Questionnaire-Modified.

Figure 2 Patient responses on the SWNS: before and after implementation of the 3-hour observation period.

Note: n, number of patients.
Abbreviation: SWNS, subjective well-being under neuroleptics scale-short form.

Figure 3 Patient responses on the SF-36: before and after implementation of the 3-hour observation period.

Notes: n=470 (before and after implementation) for the SF-12 physical, SF-12 mental, and general health subscales. n, number of patients.
Abbreviations: SF-12, 12-Item Short Form Health Survey; SF-36, 36-Item Short Form Health Survey.

Figure 4 Patient responses on the QoL scale: before and after implementation of the 3-hour observation period.

Notes: n=471 (before and after implementation) for the total score and the instrumental role subscale score. n, number of patients.
Abbreviation: QoL, quality of life.

Figure 5 PANSS total and subscale scores before and after implementation of the 3-hour observation period.

Note: n, number of patients.
Abbreviation: PANSS, Positive and Negative Syndrome Scale.